DB09205ApprovedSmall molecule
Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. According to the WHO, moxisylyte is approved since 1987 and in the same year, it... This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.
- Mechanism
- Curator reviewed · 1 reference
Moxisylyte is vasodilator that works as a specific alpha-adrenergic blocking agent. Its action is known to be competitive against norepinephrine without beta-receptor blocking, anti-angiotensin or anti-serotonin activity.
- Primary indication
- According to the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.Curator reviewed
- Formula / weight
- C16H25NO3 · 279.38 g/mol (avg)
- Also known as
- (2-(4-ACETOXY-2-ISOPROPYL-5-METHYLPHENOXY)ETHYL)DIMETHYLAMINE · 6-ACETOXYTHYMOL 2-(DIMETHYLAMINO)ETHYL ETHER · Thymoxamine
Resolves to
Clinical / RWD
Structure
InChIKey
VRYMTAVOXVTQEF-UHFFFAOYSA-NSMILESCC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1Targets
What you can answer from here — as of September 13, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Moxisylyte, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account